HSBC noted that while the market has assumed a significant market share for Eli Lilly, these expectations may be revised in ...

The CEO of Novo Holdings has warned that his $160 billion fund will slow down investment activity until the dust settles ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary, told Reuters that the firm received approval from the Thai FDA in 2023.

Todd Engel claims Ozempic caused his blindness. Lawsuit says Novo Nordisk failed to warn of rare vision risks.

In recent years our traditional understanding of both macrophages and neutrophils has been greatly challenged. Previously thought to promote inflammatory ...

Novo Nordisk has launched its popular weight-loss drug Wegovy in Thailand, marking its first entry into the Southeast Asian ...

Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...

Their own mini-boom of recent years has been largely fueled by one firm, Ozempic maker Novo Nordisk A/S, whose diabetes and ...

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...